Pernix Therapeutics Holdings (PTX) Shares are Up 6.42%

Pernix Therapeutics Holdings (PTX) has been under a strong bear grip, hence the stock is down -27.52% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.86% in the past 1 week. The stock has risen by 6.42% in the past week indicating that the buyers are active at lower levels, but the stock is down -28.99% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 7.63% and the 50-Day Moving Average is 7.95%.The 200 Day SMA reached 54.75% Pernix Therapeutics Holdings, Inc. is up 17.39% in the last 3-month period. Year-to-Date the stock performance stands at -80.34%.


Company shares have received an average consensus rating of Hold for the current week Pernix Therapeutics Holdings (NASDAQ:PTX): The stock opened at $0.55 and touched an intraday high of $0.612 on Friday. During the day, the stock corrected to an intraday low of $0.5305, however, the bulls stepped in and pushed the price higher to close in the green at $0.58 with a gain of 4.69% for the day. The total traded volume for the day was 4,766,409. The stock had closed at $0.58 in the previous trading session.

Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *